POTENTIAL OF NOVEL ANTI-INFLAMMATORY AGENTS TO SUPPRESS CHRONIC INFLAMMATION
新型抗炎药抑制慢性炎症的潜力
基本信息
- 批准号:7715651
- 负责人:
- 金额:$ 2.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-05-01 至 2009-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAngiogenesis InhibitorsAnti-Inflammatory AgentsApoptosisAsthmaBindingBinding SitesBlood PlateletsC-terminalCell AdhesionChronicComputer Retrieval of Information on Scientific Projects DatabaseDiseaseEndothelial CellsExperimental Autoimmune EncephalomyelitisFibrinFibrinogenFundingGrantIn VitroInflammationInflammatoryInstitutionIntegrinsLeukocytesModelingMultiple SclerosisMusPharmacia brand of estropipatePlayPrimatesProcessPublishingPurposeResearchResearch PersonnelResourcesRoleSignal TransductionSourceSymptomsTestingUnited States National Institutes of HealthXenograft Modeladhesion receptorangiogenesiscancer cellcell injurycell typefibrinogen D fragmentfibrinopeptides gammaimprovedkeratinocytemutantnoveltumortumor growthtumor xenograft
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Fibrin(ogen) induces proliferative signals, but some of its proteolytic fragments induce endothelial cell injury. Integrins are known to play a critical role in signal transduction from fibrin(ogen). The fibrinogen gamma chain has a C-terminal globular domain (gamma C, residues 151-411 of gamma chain, 30 Kd) to which several integrin cell adhesion receptors (e.g., platelet alpha IIb beta 3, endothelial alpha v beta 3, and leukocyte alpha M beta 2) bind. We found that the isolated gamma C fragment and its truncation mutant (gamma C399tr, 12 residue truncation) induced apoptosis of endothelial cells in vitro, while native fibrinogen or fragment D did not. gamma C or gamma C399tr did not affect proliferation of several other cell types tested including keratinocytes and cancer cells. We found that the binding site for alpha v beta 3 is cryptic in native fibrinogen and proteolytic fragment D, but is exposed in gamma C and gamma C399tr. These results suggest that gamma C and gamma C399tr are potential anti-angiogenic agents, that determinants in gamma C and gamma C399tr (which are cryptic in fibrinogen and fragment D) are involved in endothelial cell apoptosis, and that integrins are potentially involved in this process. Also we showed that gamma C399tr suppressed tumor growth in tumor xenograft models. These results were recently published [1]. Furthermore we found that gamma C399tr reduced the level of circulating endothelial cells (CEC), a marker of angiogenesis, in tumor-bearing mice (our unpublished results) and we hypothesize that this is a potential mechanism of anti-angiogenic action by gamma C399tr. It has been recently recognized that angiogenesis plays a role in chronic inflammation. We recently found that gamma C399tr markedly suppressed the onset of experimental allergic encephalomyelitis (EAE), a multiple sclerosis (MS)-like disease in mice (our unpublished results). We hypothesize that gamma C399tr may have potential as an anti-inflammatory agent as well, and suppress angiogenesis and chronic inflammation in primate.
We propose to test whether gamma C399tr may have potential as anti-angiogenic and anti-inflammatory agent in primate inflammation models. We will use the well-established primate asthma model for this purpose. We expect that gamma C399tr will show anti-angiogenic and inflammatory effects and thus improve asthma symptoms in this model.
这个子项目是众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YOSHIKAZU TAKADA其他文献
YOSHIKAZU TAKADA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YOSHIKAZU TAKADA', 18)}}的其他基金
POTENTIAL OF NOVEL ANTI-INFLAMMATORY AGENTS TO SUPPRESS CHRONIC INFLAMMATION
新型抗炎药抑制慢性炎症的潜力
- 批准号:
8357281 - 财政年份:2011
- 资助金额:
$ 2.71万 - 项目类别:
POTENTIAL OF NOVEL ANTI-INFLAMMATORY AGENTS TO SUPPRESS CHRONIC INFLAMMATION
新型抗炎药抑制慢性炎症的潜力
- 批准号:
8172556 - 财政年份:2010
- 资助金额:
$ 2.71万 - 项目类别:
Potential of a dominant-negative FGF mutant as a therapeutic in cancer
显性失活 FGF 突变体作为癌症治疗的潜力
- 批准号:
7653318 - 财政年份:2009
- 资助金额:
$ 2.71万 - 项目类别:
Potential of a dominant-negative FGF mutant as a therapeutic in cancer
显性失活 FGF 突变体作为癌症治疗的潜力
- 批准号:
8015202 - 财政年份:2009
- 资助金额:
$ 2.71万 - 项目类别:
POTENTIAL OF NOVEL ANTI-INFLAMMATORY AGENTS TO SUPPRESS CHRONIC INFLAMMATION
新型抗炎药抑制慢性炎症的潜力
- 批准号:
7959054 - 财政年份:2009
- 资助金额:
$ 2.71万 - 项目类别:
Potential of a dominant-negative FGF mutant as a therapeutic in cancer
显性失活 FGF 突变体作为癌症治疗的潜力
- 批准号:
7771748 - 财政年份:2009
- 资助金额:
$ 2.71万 - 项目类别:
Potential of a dominant-negative FGF mutant as a therapeutic in cancer
显性失活 FGF 突变体作为癌症治疗的潜力
- 批准号:
8204768 - 财政年份:2009
- 资助金额:
$ 2.71万 - 项目类别:
Integrins and the proinflammatory phospholipase A2
整合素和促炎磷脂酶 A2
- 批准号:
7142872 - 财政年份:2006
- 资助金额:
$ 2.71万 - 项目类别:
Integrins and the proinflammatory phospholipase A2
整合素和促炎磷脂酶 A2
- 批准号:
7282664 - 财政年份:2006
- 资助金额:
$ 2.71万 - 项目类别:
Characterization of Targeting Ligands-Integrin Interaction and in vitro targeting
靶向配体-整合素相互作用的表征和体外靶向
- 批准号:
6934086 - 财政年份:2005
- 资助金额:
$ 2.71万 - 项目类别:
相似海外基金
Development of Novel Lung Cancer Therapy Using Tumor-Specific Angiogenesis Inhibitors and Drug Repositioning
使用肿瘤特异性血管生成抑制剂和药物重新定位开发新型肺癌疗法
- 批准号:
21H03019 - 财政年份:2021
- 资助金额:
$ 2.71万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of biomarkers related to drug resistance of angiogenesis inhibitors
血管生成抑制剂耐药性相关生物标志物的开发
- 批准号:
20K08542 - 财政年份:2020
- 资助金额:
$ 2.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Structural and Functional Studies of Brain Angiogenesis Inhibitors (BAIs/ADGRBs)
脑血管生成抑制剂 (BAIs/ADGRB) 的结构和功能研究
- 批准号:
9813883 - 财政年份:2019
- 资助金额:
$ 2.71万 - 项目类别:
Elucidation of proteinuria expression mechanism by angiogenesis inhibitors and research on adverse effect avoidance
血管生成抑制剂蛋白尿表达机制的阐明及不良反应避免的研究
- 批准号:
17K08457 - 财政年份:2017
- 资助金额:
$ 2.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of cardiotoxicity and elucidation of cardiotoxic molecular mechanisms in cancer patients receiving angiogenesis inhibitors
接受血管生成抑制剂的癌症患者的心脏毒性评估和心脏毒性分子机制的阐明
- 批准号:
26461102 - 财政年份:2014
- 资助金额:
$ 2.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Minimally invasive response evaluation in vivo for the dual therapy of the angiogenesis inhibitors
血管生成抑制剂双重治疗的体内微创疗效评价
- 批准号:
23591763 - 财政年份:2011
- 资助金额:
$ 2.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ANGIOGENESIS INHIBITORS IN THE MULTIMODAL TREATMENT OF PEDIATRIC SOLID TUMORS
血管生成抑制剂在小儿实体瘤多模式治疗中的应用
- 批准号:
8309814 - 财政年份:2011
- 资助金额:
$ 2.71万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
7351352 - 财政年份:2008
- 资助金额:
$ 2.71万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
8002099 - 财政年份:2008
- 资助金额:
$ 2.71万 - 项目类别:
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors
针对炭疽毒素受体的新型血管生成抑制剂
- 批准号:
7615664 - 财政年份:2008
- 资助金额:
$ 2.71万 - 项目类别:














{{item.name}}会员




